Solventum (NYSE:SOLV) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPS

Solventum (NYSE:SOLV - Get Free Report) announced its quarterly earnings results on Thursday. The company reported $1.41 EPS for the quarter, beating analysts' consensus estimates of $1.31 by $0.10, Zacks reports. The business had revenue of $2.07 billion during the quarter, compared to the consensus estimate of $2.05 billion. Solventum updated its FY 2025 guidance to 5.450-5.650 EPS.

Solventum Trading Up 0.4 %

Shares of Solventum stock traded up $0.32 on Monday, hitting $80.07. 1,079,511 shares of the company traded hands, compared to its average volume of 1,450,193. The stock's 50 day moving average price is $72.78 and its 200-day moving average price is $70.20. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. Solventum has a 52 week low of $47.16 and a 52 week high of $85.92. The company has a market cap of $13.83 billion and a PE ratio of 29.12.

Analysts Set New Price Targets

A number of brokerages recently commented on SOLV. Mizuho increased their price target on shares of Solventum from $70.00 to $82.00 and gave the company a "neutral" rating in a report on Monday. Bank of America increased their price target on shares of Solventum from $80.00 to $85.00 and gave the company a "neutral" rating in a report on Wednesday, February 26th. Wells Fargo & Company increased their price target on shares of Solventum from $73.00 to $75.00 and gave the company an "equal weight" rating in a report on Friday. The Goldman Sachs Group increased their price target on shares of Solventum from $63.00 to $71.00 and gave the company a "sell" rating in a report on Monday. Finally, Piper Sandler raised their price objective on shares of Solventum from $75.00 to $84.00 and gave the stock a "neutral" rating in a research note on Friday. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has assigned a buy rating to the company's stock. According to MarketBeat, Solventum has a consensus rating of "Hold" and a consensus target price of $78.86.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.